Cell Genesys Invites You to Join Its Company Presentation at the BIO CEO And Investor Conference on the Web
NEW YORK, Feb. 20 /PRNewswire-FirstCall/ -- In conjunction with Cell Genesys' (Nasdaq: CEGE - news) company presentation at the BIO CEO and Investor Conference, you are invited to listen to the presentation that will be broadcast live over the Internet on Friday, February 22, 2002, at 8:30 a.m. EST with Stephen A. Sherwin, M.D., chairman and chief executive officer of Cell Genesys.
What: Cell Genesys Company Update
BIO CEO and Investor Conference
When: Friday, February 22, 2002, at 8:30 a.m. EST
Where: www.cellgenesys.com
How: Live over the Internet -- Simply log on to the web at the
address above
Contact: Jennifer Cook Williams
650-425-4542
Cell Genesys is focused on the development and commercialization of innovative therapeutic products for cancer based on gene therapy technologies. The company is pursuing three cancer product platforms -- GVAX® cancer vaccines, oncolytic virus therapies and in vivo cancer gene therapies. Clinical trials of GVAX® vaccines are under way in prostate cancer, lung cancer, pancreatic cancer, leukemia and myeloma. Clinical trials of oncolytic virus therapies include CG7060 and CG7870 in prostate cancer. Preclinical stage programs include oncolytic virus therapies and gene therapies for multiple types of cancer. Cell Genesys' majority-owned subsidiary, Ceregene, is focused on gene therapies for neurologic disorders. Cell Genesys also continues to hold approximately nine million shares of common stock in its former subsidiary, Abgenix, an antibody products company. Cell Genesys is headquartered in Foster City, CA and has manufacturing operations in San Diego, CA, Hayward, CA and Memphis, TN. For additional information, please visit the company's website at www.cellgenesys.com.
If you are unable to listen to the live webcast, the presentation will be archived on www.cellgenesys.com and will be available within one hour following the presentation for two weeks.
SOURCE: Cell Genesys, Inc. |
